GrantWise
HORIZON EUROPE TOPIC · Cluster 1 · Health

Innovative healthcare interventions for non-communicable diseases

HORIZON-HLTH-2027-02-DISEASE-01-two-stage — the expected outcomes as checkable statements, what evaluators look for in this topic, and the conditions that shape the proposal.

Get the free Part B working draft for this topic ↓

ForthcomingRIA · lump sumDeadline 17 February 2027EUR 7 million to EUR 8 million per project

GrantWise › Horizon Europe topics › HORIZON-HLTH-2027-02-DISEASE-01-two-stage

TopicHORIZON-HLTH-2027-02-DISEASE-01-two-stage
StatusForthcoming
CallHORIZON-HLTH-2027-02-two-stage — Cluster 1 - Health (Two stage - 2027)
DestinationTackling diseases and reducing disease burden (2026-27)
Type of actionResearch and Innovation Actions · lump sum · two-stage
Opening29 October 2026
Deadlines17 February 2027 (stage 1) · 16 September 2027 (stage 2)
BudgetEUR 7 million to EUR 8 million per project · 8 projects expected · EUR 63.8 million in total
Part B page limit45 pages (standard application form; check your call)
TemplateWork Programme 2026–2027 application form

Expected outcomes

Projects should contribute to all of the expected outcomes. The topic says: “This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:”

  1. EO1 Researchers, developers and clinical practitioners have access to state-of-the-art knowledge, data, technologies, tools, methods, best practices, and trainings to develop innovative healthcare interventions aimed at reducing burden of the following specific Non-Communicable Diseases (NCDs): cardiovascular diseases, diabetes, chronic respiratory diseases or chronic kidney diseases.
  2. EO2 Scientific and clinical communities can use innovative healthcare interventions to generate meaningful advances in clinical practice and care for patients with NCDs following validation in late-stage clinical trials.
  3. EO3 Scientific and clinical communities make wide use of relevant databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR principles, thereby encouraging further use of the data.
  4. EO4 Policymakers, scientific and clinical communities, developers, patient organisations, regulators, and other relevant bodies are informed of the research advances made and the requirements for a widespread implementation of the innovative therapeutic interventions and complementary approaches.
  5. EO5 Patients and caregivers are constructively engaged with the research, ensuring that their needs are catered for, with the aim of tangibly benefitting from the interventions.

Expected impacts named in the destination

The wider, long-term effects the destination seeks. Your outcomes feed them; they are not project deliverables.

  1. EI1 Disease burden in the EU and worldwide is reduced through effective disease management, including through the development and integration of innovative preventive, diagnostic and therapeutic approaches, digital and other people-centred solutions for healthcare.
  2. EI2 Premature mortality from non-communicable diseases is reduced by one third (by 2030), mental health and wellbeing are promoted, and the targets of the World Health Organization (WHO) Global Action Plan for the Prevention and Control of non-communicable diseases, are attained, with an immediate impact on the related disease burden (Disability-Adjusted Life Years - DALYs).
  3. EI3 Healthcare systems benefit from strengthened Research and Innovation expertise, human capacities and know-how for combatting communicable and non-communicable diseases, including through international cooperation.
  4. EI4 Citizens benefit from reduced (cross-border) health threat of epidemics and AMR pathogens, in the EU and worldwide,,.
  5. EI5 Patients and citizens are knowledgeable of disease threats, involved and empowered to make and shape decisions for their health, and better adhere to knowledge-based disease management strategies and policies (especially for controlling outbreaks and emergencies).

What evaluators will look for in this topic

Expected outcomes

  • Projects should contribute to all of the expected outcomes.
  • For each outcome (EO1 to EO5), name who will use or adopt your results (a specific group, not “industry” or “society”), how they get them, and the indicator that shows the change, with baseline, target and date.
  • Use the topic's own words for each outcome, so the evaluator can tick it off.

What the scope asks for

Evaluators check the proposal against these sentences of the scope. Answer each one visibly, in the call's own words.

  • “Innovative and effective healthcare interventions are required to provide treatment and disease management solutions and assure best quality of care for patients suffering from NCDs when prevention strategies have failed.”
  • “Proposals should address all the following aspects:.”
  • “Whenever relevant, existing co- and multimorbidities should be addressed in the trial design.”
  • “Clinical trial(s) should be supported by completed proof-of-concept of clinical safety and efficacy.”
  • “Both preclinical research and the draft clinical trial protocol should be completed at the time of submission of the proposal.”
  • “Proposals should also demonstrate evidence of preliminary consultations with ethics and regulatory authorities at the time of submission.”
  • “A sound feasibility assessment, including an appropriate patient selection and realistic recruitment plans, justified by publications or preliminary results should be provided.”
  • “Hardware and software should be interoperable in line with internationally accepted standards.”
  • “Exploit existing data, health data infrastructures, biobanks, registries and/or cohorts, together with the generation of new data that should be managed in line with the FAIR principles and contribute to emerging research infrastructures established in the framework of the European Health Data Space (EHDS), when relevant.”
  • “The participation of start-ups, micro, small and medium-sized enterprises (SMEs) is encouraged with the aim of strengthening their scientific and technological foundations, enhancing their innovation potential, and exploring possibilities for commercial exploitation.”
  • “This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.”
  • “All projects funded under this topic are encouraged to participate in networking and joint activities, as appropriate and explore potential synergies with projects funded under the EU4Health Programme (2021-2027) in the area of NCDs.”

Conditions that shape the proposal

  • Part B, sections 1–3: 45 pages (standard application form). Text beyond the limit is not read; tables and figures count.
  • Lump sum: the budget is fixed per work package and paid when each work package is completed. Every work package needs activities and deliverables an evaluator can verify, and the effort must match the money.
  • Two-stage submission: the first stage uses a shorter proposal and is assessed on Excellence and Impact only. Check the page limit and sections in the stage-one form of your call.
  • Admissibility Conditions, proposal page limit and layout: “Applicants submitting a proposal for a blind evaluation (see General Annex F) must not disclose their organisation names, acronyms, logos nor names of personnel in the proposal abstract and Part B of their first-stage application (see General Annex E).”
  • Other Eligibility Conditions: “In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.”
  • Other Eligibility Conditions: “Subject to restrictions for the protection of European communication networks.”
  • Evaluation and award: Award criteria, scoring and thresholds: “The first-stage proposals of this topic will be evaluated blindly.”
  • Evaluation and award: Submission and evaluation processes: “For the first stage, the thresholds for each criterion will be 4 (Excellence) and 4 (Impact). The overall threshold applying to the sum of the two individual scores will be set at a level that ensures the total requested budget of proposals admitted to stage 2 is as close as possible to three times the available…”
  • Evaluation and award: Submission and evaluation processes: “For the second stage, the thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.”

Impact pathway and traps

  • The topic asks for social sciences and humanities (SSH) expertise. Evaluators look for SSH partners with a real role in the methodology, not a token task.
  • Users or citizens are part of the scope. Show how they take part in the design and testing, not only that they are informed.
  • The scope expects pilots or demonstration. Name the sites, the partners who run them and what is measured there.
  • The topic expects cooperation with other projects or initiatives. Reserve effort and budget for it in the work plan.
  • Open science or data practices are named. Make the data management plan concrete: which data, which repository, when.
  • The gender dimension is named in the topic. Show how sex and gender analysis enters the research content, not only team balance.
  • Policy or regulation is in scope. Name the policy owners you will reach and what you will give them.
  • Keep outputs, outcomes and impacts apart: what you deliver, what changes when others use it, and the long-term effect.
  • For each destination impact you claim, show which of your outcomes feeds it. Destination impacts are long-term effects, not project deliverables.
  • Name the barriers outside the project (regulation, markets, user behaviour) that could block uptake, and what you will do if they do.
  • Section 2.3 (the summary canvas) is optional on this call; the old split into scientific, economic and societal impact is no longer required.
The scope, as published

NCDs represent over 80% of the disease burden in Europe and the leading cause of avoidable premature deaths. Innovative and effective healthcare interventions are required to provide treatment and disease management solutions and assure best quality of care for patients suffering from NCDs when prevention strategies have failed. Proposals should address all the following aspects: Perform rigorous early stage clinical trial(s) to validate novel or refined healthcare interventions for treatment and/or disease management solutions for patients suffering from the following specific NCDs: cardiovascular diseases, diabetes, chronic respiratory diseases or chronic kidney diseases. Whenever relevant, existing co- and multimorbidities should be addressed in the trial design. Clinical trial(s) should be supported by completed proof-of-concept of clinical safety and efficacy. Both preclinical research and the draft clinical trial protocol should be completed at the time of submission of the proposal. Proposals should also demonstrate evidence of preliminary consultations with ethics and regulatory authorities at the time of submission. A sound feasibility assessment, including an appropriate patient selection and realistic recruitment plans, justified by publications or preliminary results should be provided. Take into account sex and gender differences in all relevant aspects throughout the research process, and consider stratification criteria such as age, disability, racial or ethnic origin, socio-economic status, genetic and epigenetic variations, etc., where relevant. Use and/or develop technologies, including digital ones (e.g. (generative) Artificial Intelligence, wearable technologies) to help implement and monitor the long-term efficacy of the intervention(s), as well as manage the disease and/or monitor their progression (e.g. with unobtrusive technologies suitable for patient monitoring at home and in real-world conditions), whilst also ensuring they are bias-free, inclusive, and ethically sound. Hardware and software should be interoperable in line with internationally accepted standards. The use of virtual human twins could also be considered, where relevant. Exploit existing data, health data infrastructures, biobanks, registries and/or cohorts, together with the generation of new data that should be managed in line with the FAIR principles and contribute to emerging research infrastructures established in the framework of the European Health Data Space (EHDS), when relevant. Advance research by leveraging already existing and emerging state-of-the-art research infrastructures as well as results stemming from EU-supported research projects, where applicable. Engage all relevant stakeholders (especially patients and patients’ representatives, caregivers, clinicians, counsellors, regulators, etc.) to design end-user optimised interventions. Engage with national public health authorities and regulators to ensure a robust development pathway and further uptake of the intervention. Present a thorough health-economic assessment and Real-World Data (RWD) analysis to enhance sustainability and scalability of novel interventions. The participation of start-ups, micro, small and medium-sized enterprises (SMEs) is encouraged with the aim of strengthening their scientific and technological foundations, enhancing their innovation potential, and exploring possibilities for commercial exploitation. This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities. All projects funded under this topic are encouraged to participate in networking and joint activities, as appropriate and explore potential synergies with projects funded under the EU4Health Programme (2021-2027) in the area of NCDs. Applicants invited to the second stage should provide details of their clinical studies in the dedicated annex using the template provided in the submission system. As proposals under this topic are expected to include clinical studies, the use of the template is strongly encouraged. See definition of FAIR data in the introduction to this Work Programme part. For pharmacological interventions: phase 1 and/or phase 2 clinical trials. Applicants may address any mono- or combinatorial pharmacological and/or non-pharmacological interventions. Other diseases are not within the scope of this topic. Comparative effectiveness studies are not within the scope of this topic. The use of the term ‘racial or ethnic origin’ does not imply an acceptance of theories that attempt to determine the existence of separate human races. For digital technologies concerned, appropriate measures for the security of the communications between the intended parties should be considered, in particular based on the use of post-quantum cryptography. https://digital-strategy.ec.europa.eu/en/policies/virtual-human-twins For instance BBMRI, ELIXIR, EU-OPENSCREEN, ECRIN, EATRIS, etc. https://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space-regulation-ehds_en EMA definition: “Real-World Data are routinely collected data relating to patient health status or the delivery of healthcare from a variety of sources other than traditional clinical trials (e.g. claims databases, hospital data, electronic health records, registries, mhealth data, etc.)”. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32003H0361 Proposals should include a budget for the attendance to regular joint meetings and may consider covering the costs of any other potential joint activities without the prerequisite to detail concrete joint activities at this stage. The details of these joint activities will be defined during the grant agreement preparation phase.…

Other topics in HORIZON-HLTH-2027-02-two-stage

Source and attribution

Topic text from the official topic page on the EU Funding & Tenders Portal, retrieved 19 October 2026. © European Union, reused under Commission Decision 2011/833/EU (CC BY 4.0). Changes: the expected outcomes and impacts are split into numbered statements, long passages are shortened, and the evaluator checklist is GrantWise's own commentary. Your call and the Work Programme always win; check them before you submit. GrantWise is independent and not affiliated with, endorsed by, or acting on behalf of the European Commission.